At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 90 enrolled
Drug / intervention
Carbamazepine +1 moredrug
Likely dose
Carbamazepine 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Carbamazepine and Oxcarbazepine on Serum Neuron-specific Enolase and S100B in Focal Seizures
All India Institute of Medical Sciences, Bhubaneswar·interventional·Posted Mar 11, 2016·Updated Sep 19, 2017
In Brief
A Phase 4 clinical trial evaluating Carbamazepine and Oxcarbazepine for Seizures, Focal. Completed, enrolled 90 participants across 1 site.
Detailed Summary
The present study has been planned to assess the level of serum neuron-specific enolase (NSE) in focal seizures and its changes after antiepileptic therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeizures, Focal
CountriesIndia
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartApr 2016
Primary CompletionFeb 2017
Study CompletionMar 2017
TodayJul 2026
First PostedMar 11, 2016
Enrollment StartApr 1, 2016
Primary CompletionFeb 1, 2017
Study CompletionMar 1, 2017
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 10.3 years ago
Interventions
Carbamazepinedrug
Carbamazepine will be started with a dose of 200 mg/day for one week and then increased to 400 mg/day for one week and then 600mg/day for next two weeks.
Oxcarbazepinedrug
Oxcarbazepine will be started with 10mg/kg daily dose for one week followed by 15mg/kg daily for next one week and then will be increased to 20mg/kg for next two weeks.